Form 4: Tenax Therapeutics CEO Awarded Stock Options
Executive Compensation Disclosure
Tenax Therapeutics CEO, Christopher Thomas Giordano, was granted stock options on December 10, 2024, with vesting schedules extending to 2028.
Summary
- Tenax Therapeutics CEO, Christopher Thomas Giordano, received stock options on December 10, 2024.
- The options include 1,250,000 shares at an exercise price of $5.94, vesting between 2025 and 2034.
- Additional options include 3,152 shares vesting from 2022 to 2025, 992 shares vesting from 2023 to 2026, and 3,549 shares vesting from 2025 to 2028.
- Vesting for all options is contingent upon the CEO's continued employment with the company.
Sentiment
Score: 7
Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.
Positives
- The granting of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Risks
- The value of the options is dependent on the future performance of the company's stock price.
- The CEO's departure would result in the forfeiture of unvested options.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for CEOs in the biotech industry, similar to companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals.
- The vesting schedules are typical, with options vesting over a period of several years to encourage long-term performance.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes the CEO to increase shareholder value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 2022-07-06 | First vesting date for 25% of 3,152 stock options. |
| 2023-06-09 | First vesting date for 25% of 992 stock options. |
| 2023-07-06 | Second vesting date for 25% of 3,152 stock options. |
| 2024-06-09 | Second vesting date for 25% of 992 stock options. |
| 2024-07-06 | Third vesting date for 25% of 3,152 stock options. |
| 2024-12-10 | Date of grant for 1,250,000 stock options. |
| 2024-12-12 | Date of filing of the document. |
| 2025-05-17 | First vesting date for 25% of 3,549 stock options. |
| 2025-06-09 | Third vesting date for 25% of 992 stock options. |
| 2025-07-06 | Final vesting date for 25% of 3,152 stock options. |
| 2025-12-10 | First vesting date for 1,250,000 stock options. |
| 2026-05-17 | Second vesting date for 25% of 3,549 stock options. |
| 2026-06-09 | Final vesting date for 25% of 992 stock options. |
| 2027-05-17 | Third vesting date for 25% of 3,549 stock options. |
| 2028-05-17 | Final vesting date for 25% of 3,549 stock options. |
| 2031-07-06 | Expiration date for 3,152 stock options. |
| 2032-06-09 | Expiration date for 992 stock options. |
| 2034-05-17 | Expiration date for 3,549 stock options. |
| 2034-12-10 | Expiration date for 1,250,000 stock options. |
Keywords
stock options, CEO, Tenax Therapeutics, equity compensation, vesting, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.